In this work, we investigated the IgM, IgA and IgG antibody profiles directed to SARS-CoV-2 antigens, as well as antibody neutralizing capacity, in COVID-19 individuals with different disease outcomes, aiming to determine whether specific profiles were associated with COVID-19 severity or recovery, suggesting potential beneficial versus deleterious antibody functions in COVID-19. The gene discussed is CD40LG; the disease is COVID-19.